Genomics

Gene editing in 2025-2026 has entered a phase transition from proof-of-concept to clinical reality — and as of mid-2026 it has cleared the highest clinical bar yet. In vivo CRISPR succeeded in a Phase 3 trial for the first time: Intellia's lonvoguran ziclumeran (lonvo-z, NTLA-2002) cut hereditary angioedema attacks 87% vs placebo (p<0.0001) from a single 50 mg LNP infusion that inactivates the liver KLKB1 gene — a global first for the modality, now in a rolling BLA with a US launch targeted for 1H 2027. Casgevy (approved 2023, ex vivo) remains the only approved CRISPR therapy, but 50+ CRISPR trials are now recruiting, and base editing has broken through across AATD, PKU, sickle cell, and cardiovascular disease (Beam, Verve). The earlier Cleveland Clinic result — a single CRISPR infusion that cut LDL cholesterol 50% — now reads as the opening move of an in vivo wave rather than an isolated proof.

Three other forces are reshaping the trajectory. AI-designed biology crossed from copilot (CRISPR-GPT) to creator: Profluent's OpenCRISPR-1 is the first fully AI-generated gene editor to edit the human genome (95% off-target reduction vs SpCas9). Longevity reprogramming crossed from mouse to Phase 1 humans: Life Biosciences' FDA-cleared partial epigenetic reprogramming trial (Yamanaka OSK, eye-targeted). And the read-out layer matured: long-read sequencing's accuracy tax is largely paid down (PacBio HiFi 99.9–99.95%, Oxford Nanopore ~99%), with single-cell + long-read convergence (SCLR-seq) now resolving full-length isoforms per cell — the substrate beneath both edit validation and the single-cell aging atlases precision longevity depends on.

Frontier — What's Moving Now

• In vivo CRISPR clears Phase 3 — Intellia lonvo-z (HAE): 87% attack reduction, single dose, rolling BLA, 1H 2027 launch. First-ever for the modality.
• Base editing breaks through in the clinic — Beam (AATD first-ever correction, PKU IND, sickle cell) + Verve (PCSK9, 69% LDL). "Safer CRISPR," in vivo, corrective.
• Long-read sequencing hits the clinic — PacBio HiFi 99.9–99.95% + ONT ~99%; SCLR-seq resolves isoforms per single cell.
• AI-designed gene editors — OpenCRISPR-1 (Profluent, Nature 2025), first fully AI-generated editor to edit the human genome. 95% off-target reduction.
• Partial epigenetic reprogramming in humans — Life Biosciences FDA approval Jan 2026; Phase 1 in glaucoma + NAION with OSK + doxycycline switch.
• Disease-agnostic prime editing — Suppressor tRNAs address ~30% of rare diseases. Error rates improved to 1-in-101.
• Epigenetic editing without DNA cuts — Demethylation-based gene activation, applied to Sickle Cell.
• One-time cardiovascular treatment — CRISPR infusion cuts LDL -50%, triglycerides -55% in 15 patients.
• Precision longevity framework — Baylor review argues single-cell atlas integration is required; the human atlas gap is the translation bottleneck.

Concept Map

Concepts

Entities

Timeline

See timeline.md for chronological developments.

Research Frontier

See frontier.md for active research directions, breakthroughs, and knowledge gaps.

Sources